All News

RheumNow Podcast square

Gout Cavalcade (7.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article
CAR-T

CAR-T Therapy: EULAR 2026 Conference Recap

Jack Cush, MD

CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.

Read Article
NEJM.Magnify

NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

MedPage Today

The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic

Read Article
lung.ILD.MD

DMARD Efficacy in RA-ILD

Jack Cush, MD

A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional, low-certainty recommendations.

Read Article
uric%20acid.crystals.gout_.JPG

Uric Acid: Is Lower Better?

Joshua Baker, MD, MSCE,  , Brian Coburn, MD, PhD

Lowering serum urate and urate crystals in the body is indispensable for long-term management of gout. The pathophysiology is simple and powerful: no urate crystals, no gout flares.

Read Article
Eosinophil

ICYMI: EGPA Review

Jack Cush, MD

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

Read Article
guidelines.jpg (keep)

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Jack Cush, MD

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

ICYMI: B Cells at the Brink in Sjögren Disease

Jack Cush, MD

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Read Article
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease. Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz #CARTCellTherapy https://t.co/kaTom2dEnZ

Links:

Dr. John Cush RheumNow ( View Tweet)
< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl). For more gout content, follow our Gout: More than Flares campaign at https://t.co/j3iLMZz4HM, https://t.co/zFTozS62me

Links:

Dr. John Cush RheumNow ( View Tweet)
The global Chronic Refractory Gout Market is projected to grow from ~$2.94 billion USD in 2022 to nearly $10.07 billion USD by 2036, reflecting introduction of innovative therapies. Chronic Refractory Gout in the 7Major Markets exceeded 400,000 pts in 2025 (>200K in USA) https://t.co/MSzBNTXTPj
Dr. John Cush RheumNow ( View Tweet)
Whats the BEST FIRST Rx in DMARD-Naive #RA - Tofacitinib or MTX. RCTs (ORAL Start, RA-BEGIN, SELECT-EARLY, FINCH 3) prove JAKi > MTX. A recent 116 RCT from China also shows Tofa > MTX by SDAI50 (94% v 75%) @3 mos & Tofa was more cost effective. https://t.co/KL2qlDgF6D https://t.co/wNVBgQkaMI

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY>> Which Gout drugs lower the risk of cardiovascular death? Answer here: https://t.co/1OY1B3ET7B https://t.co/MRJP5OOtXb

Links:

Dr. John Cush RheumNow ( View Tweet)
Insights into Treating Lupus - A Rheum Survey RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush RheumNow ( View Tweet)
RT @rheumarampa "There’s more work to do” as Dr. Floris van Gaalen summarizes the challenges in peripheral SpA -pSpA has limited lab value testing like imaging, clinical diagnosis - few clinical trials to support tx guidelines - SPARTACUS trial: GOL vs. MTX in early pSpA

Dr. John Cush RheumNow ( View Tweet)

RT @yuz6yusof #EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE

Dr. John Cush RheumNow ( View Tweet)

RT @aurelierheumo A long release version of xanthine oxidase inhibitor in gout -442 pts 36 wks -HR091506 vs febuxostat -SUA <300 μmol/L: 63.8% vs 40.7% (Δ +22.9%, p<0.0001) -higher SUA reduction vs baseline -Similar overall TEAEs (~90%) A molecule to keep an eye on! #LB0008

Dr. John Cush RheumNow ( View Tweet)

ICYMI: B Cells at the Brink in Sjögren Disease The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush RheumNow ( View Tweet)
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous &amp; MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026

Dr. John Cush RheumNow ( View Tweet)

Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×